EXHIBIT 10.2
DISTRIBUTION AGREEMENT
----------------------
This Distribution Agreement (hereinafter "Agreement") is made as of
April 3, 1998, by and between Centocor, Inc., a Pennsylvania corporation
("Centocor"), and Schering-Plough Ltd., a Swiss corporation ("Schering-Plough").
Centocor has developed an anti-TNF chimeric monoclonal antibody
product (cA2, infliximab, Avakine/(TM)/) (the "Product") for use as an agent in
the treatment of (a) inflammatory bowel diseases, including Crohn's Disease
(collectively referred to as "Inflammatory Bowel Disease"); (b) rheumatoid
arthritis; and (c) new indications to be defined. A description of the Product
is set forth in the attached Appendix A. The Product also includes Improvements,
if any, as defined in Section 1.9.
Subject to obtaining necessary Regulatory Approvals, Centocor and
Schering-Plough wish to set forth the manner in which, and the terms under
which, they have agreed to commercialize the Product.
Therefore, the parties, for good and valuable consideration, the
receipt and adequacy of which is hereby acknowledged by each of them, and
intending to be legally bound, agree as follows.
ARTICLE I
DEFINITIONS
-----------
For purposes of this Agreement, the following terms, when used with
initial capital letters, will have the meaning set forth below. Other terms are
defined elsewhere in this Agreement and those terms, when used with initial
capital letters, will also have the defined meanings whenever they appear in
this Agreement. As to the terms defined and used herein, the singular will be
understood to include the plural and vice-versa, unless the context clearly
indicates to the contrary.
1.1 "AFFILIATE" means any person or entity directly or indirectly
Controlling, Controlled by or under common Control with a party hereto. Any
reference in this Agreement to Centocor or Schering-Plough includes the
Affiliates of that party unless the context clearly indicates to the contrary.
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
1.2 "AGREEMENT YEAR" means, initially, the period from the Effective
Date of this Agreement through December 31, 1998, or the earlier termination of
this Agreement, and thereafter, each calendar year during the term of this
Agreement or part thereof which ends at the point of expiration or termination
of this Agreement.
1.3 "COMMERCIAL SALES" means, for any applicable period, the amount
invoiced for Product sold by Schering-Plough or its Affiliates to unaffiliated
parties, exclusive of intercompany transfers.
1.4 "CONTROL" means the ability of any entity (the "Controlling"
entity), directly or indirectly, through ownership of securities, by agreement
or by any other method, to direct the manner in which more than fifty percent
(50%) of the outstanding voting rights of any other entity (the "Controlled"
entity), whether or not represented by securities, shall be cast, or the right
to receive over fifty percent (50%) of the profits or earnings of, or to
otherwise control the management decisions of, such other entity (also a
"Controlled" entity).
1.5 "CORE CO-PROMOTION TERRITORY" shall mean all of the following
countries: Germany, France, Italy, Spain and the United Kingdom.
1.6 "COST OF GOODS SOLD" means: (a) the costs of direct material
purchased for use in the production process; (b) depreciation, repair,
maintenance and operating costs of the production facilities utilized in the
production of the Product; (c) the costs of quality, stability and in-process
controls; (d) building operating costs, other than any included in subpart (b)
above; (e) direct labor costs and overheads calculated in conformity with U.S.
generally accepted accounting principles; (f) the costs of mutually agreed,
noncapitalized manufacturing process improvement and cost reduction efforts; and
(g) the costs of filling, finishing and packaging; provided, however, that the
Cost of Goods Sold for the finished Product will not exceed [*] per gram of
labelled Product. "Cost of Goods Sold" excludes the costs of research batches.
This definition of "Cost of Goods Sold" is intended to be consistent with
Appendix B.
1.7 "EFFECTIVE DATE" means the date first set forth above.
1.8 "EMEA APPROVAL" means the issuance by the European Agency for the
Evaluation of Medicinal Products (the "EMEA") of the marketing authorization
(excluding any pricing approvals) necessary for the sale of Product within the
European Community for one or more indications.
CONFIDENTIAL TREATMENT REQUESTED.
2
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
1.9 "IMPROVEMENT" means any change with respect to the Product,
including, without limitation, any change in the formulation, dosage, mode of
delivery or new indications for the Product, any change in the Product resulting
from a change in the manufacturing process, and any chimeric or humanized anti-
TNF monoclonal antibody or fragment thereof, other than the Product as described
in Appendix A, developed by or licensed to Centocor.
1.10 "MARKETING APPROVAL" means Regulatory Approval, pricing approval
and reimbursement approval, where applicable.
1.11 "MARKETING EXPENSES" means [*].
1.12 "NET SALES" means, for each applicable period, the Commercial
Sales for that period, less reasonable and customary deductions from such gross
amounts, including: (a) normal and customary trade, cash and quantity
discounts, allowances and credits; (b) credits or allowances actually granted
for damaged goods, returns or rejections of Product and retroactive price
reductions; (c) sales or similar taxes when included in billing (including
duties or other governmental charges levied on, absorbed or otherwise imposed on
the sale of Product including, without limitation, value added taxes or other
governmental charges otherwise measured by the billing amount); (d) charge back
payments and rebates granted to managed health care organizations or their
agencies, and purchasers and reimbursers or to trade customers, including but
not limited to, wholesalers and chain and pharmacy buying groups; (e)
commissions paid to third parties other than sales personnel and sales
representatives, sales agents or distributors; and (f) rebates (or equivalents
thereof) granted to or charged by national, state or local governmental
authorities in a country in the Territory, to the extent specifically associated
with Commercial Sales of the Product.
1.13 "PRODUCT" means the anti-TNF chimeric monoclonal antibody product
(cA2, infliximab, Avakine/(TM)/) developed by Centocor for use as an agent in
the treatment of (a) inflammatory bowel diseases, including Crohn's Disease
(collectively referred to as "Inflammatory Bowel Disease"); (b) rheumatoid
arthritis; and (c) new indications to be defined. A description of the Product
is set forth in the attached Appendix A. The Product also includes Improvements,
if any, as defined in Section 1.9.
1.14 "PRODUCT DEVELOPMENT COSTS" means all external costs, including
external product development costs, incurred by Centocor and Schering-Plough
after the Effective Date in connection with the clinical development (including
pre-clinical, toxicology, pharmacology and pharmacodynamic studies and clinical
trials, except as limited by the last
CONFIDENTIAL TREATMENT REQUESTED.
3
sentence of this definition) and clinical support of regulatory filings with
respect to the Product. "Product Development Costs" also includes the cost of
goods for material used in clinical trials, which cost will be calculated based
on Centocor's Cost of Goods Sold, or, if Centocor contracts with a third party
for manufacture of the Product, will be the actual cost paid by Centocor to that
third party. "Product Development Costs" also includes such costs of the
development of improvements of manufacturing and control processes as are
incurred after the Product has received a first EMEA Approval. All internal
costs of Centocor or Schering-Plough, including but not limited to salaries,
payroll taxes, bonuses and benefits incurred with respect to their employees and
office, administration and overhead expenses, are specifically excluded from the
definition of "Product Development Costs," unless otherwise agreed by the
parties. Excluded from "Product Development Costs" are costs incurred with
respect to clinical trials or other studies undertaken solely to support
applications for Regulatory Approval outside the Territory.
1.15 "REGULATORY APPROVAL" means, as to the United States and each
country in the Territory in which approval may be required, the issuance by the
relevant governmental body or bodies or other organization or organizations of
all licenses, approvals and registrations necessary for the sale of the Product
within such country for a particular indication or indications (excluding any
pricing approvals).
1.16 Subject to Section 2.2(a), "TERRITORY" means the world except for
the United States, Japan, Taiwan, Indonesia and the People's Republic of China
(including Hong Kong).
ARTICLE II
DISTRIBUTION AND PROMOTION OF THE PRODUCT
-----------------------------------------
2.1 DISTRIBUTION AND PROMOTION PLAN. Subject to the further terms
-------------------------------
and conditions described below, Centocor and Schering-Plough agree on the
following distribution and promotion plan for the Product, all subject to the
receipt of the necessary Regulatory Approvals, wherever required.
(a) EXCLUSIVE DISTRIBUTION BY SCHERING PLOUGH. Centocor will sell the
-----------------------------------------
Product to Schering-Plough on an exclusive basis for resale by Schering-Plough
in each country within the Territory in which Schering-Plough may lawfully sell
the Product. Subject to any regulatory restrictions on price in any of the
countries in the Territory, Schering-Plough will set the selling price of the
Product in the Territory to unaffiliated parties.
4
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
In those countries in which governmental approval of pricing is required or
desirable, Schering-Plough will have the responsibility for seeking such
approval; and Centocor will appoint Schering-Plough to act as its agent in
seeking such approval and will otherwise cooperate with and provide reasonable
assistance to Schering-Plough. Notwithstanding any other provision of this
Agreement, Schering-Plough will not have any obligation to launch the sale of
the Product in any country in the Territory in which governmental approval of
pricing is required or desirable, but in which Schering-Plough is unable to
obtain approval of pricing which is satisfactory in the view of the Product
Committee. Schering-Plough will, on an exclusive basis, distribute (or cause
the distribution of) and, subject to Section 2.1(b), market the Product in all
countries in the Territory in which Marketing Approval for the Product has been
granted. Centocor will participate in promotional support and educational
support activities with respect to the Product in the Territory in a manner to
be discussed and approved from time to time by the Product Committee.
(b) CO-PROMOTION OF THE PRODUCT IN THE TERRITORY. If, at the
--------------------------------------------
conclusion of the [*] full Agreement Year after both of the milestones set forth
in Section 3.3 have been achieved, Net Sales of the Product in the Territory are
less than [*] in that [*] full Agreement Year, Centocor shall thereafter have
the option to co-promote the Product with Schering-Plough, using its own
resources or resources contracted from others, in the Core Co-Promotion
Territory. Centocor may exercise its co-promotion option by providing written
notice to Schering-Plough to that effect; provided, however, that Centocor's co-
promotion option will expire on the [*] day of the [*] full Agreement Year after
the milestones set forth in Section 3.3 have been achieved. Upon exercising the
co-promotion option, Centocor shall be obligated to perform fifty percent (50%)
of the details (as determined by the Product Committee) in the Core Co-promotion
Territory. Centocor's co-promotion option shall be contingent upon Centocor
having in place at the time the option is exercised an adequate field sales
force to perform such activities. The remaining terms pursuant to which
Centocor and Schering-Plough will co-promote the Product should this contingency
arise, including the potential expansion of the Core Co-Promotion Territory,
will be determined by the Product Committee, subject to the terms of Section
[*]. If one or both of the milestones set forth in Section 3.3 are not achieved
but the Product nevertheless has received Marketing Approval and has been sold
for Crohn's Disease and rheumatoid arthritis indications for [*] full Agreement
Years in the Core Co-promotion Territory and Net Sales in the Territory in that
[*] full Agreement Year are less than [*], the Product Committee shall discuss
whether Centocor should have the option to co-promote the Product, at a minimum
in the Core Co-promotion Territory and possibly in other countries in the
Territory.
CONFIDENTIAL TREATMENT REQUESTED.
5
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
(c) OTHER INDICATIONS. The parties, through the Product Committee,
-----------------
may from time to time consider development of the Product for indications other
than Inflammatory Bowel Disease or rheumatoid arthritis. In the event that the
Product Committee determines to pursue the development of the Product for any
such other indication, the parties will share [*] the Product Development Costs
for such new indication incurred after the date of the Product Committee's
determination. Following Regulatory Approval, Schering-Plough shall have the
exclusive rights in the Territory to market, promote, distribute, offer for sale
and sell the Product for such new indications. In the Territory, the
Contribution Income split with respect to Commercial Sales for such new
indication will be as set forth in Section 6.2.
For any such new indications, Centocor may, at its discretion, grant
to Schering-Plough's United States Affiliate, Schering Corporation, an option to
co-promote the Product in the United States for any such new indication. Such
option must be exercised by providing written notice to Centocor no later than
[*] days after the successful completion of one or more Phase II clinical trials
establishing proof of efficacy for the Product for such indication which
supports undertaking a Phase III clinical study. During the [*] day period
prior to the date Schering Corporation must exercise the option, Schering
Corporation will conduct any due diligence review reasonably necessary to enable
Schering Corporation to determine whether or not to exercise its option rights.
If Schering Corporation elects to exercise its option, it will make a payment to
Centocor or offer to Centocor United States co-promotion rights to a Schering
Corporation product. The amount of such payment, or the Schering Corporation
product to be co-promoted by Centocor and the terms of such co-promotion by
Centocor, will be negotiated at the time Schering Corporation exercises its
option. If Schering Corporation elects to exercise its option, the parties will
enter into a suitable agreement under essentially the same terms as set forth
herein and will share equally the Contribution Income, as that term is defined
in Section 6.2, from Commercial Sales in the United States for such new
indication; however, in the Territory the Contribution Income split with respect
to Commercial Sales for such new indication will be as set forth in Section 6.2.
If Schering Corporation elects not to exercise its option, Centocor will retain
one hundred percent (100%) of Contribution Income from Commercial Sales in the
United States for such new indication.
The parties will discuss in good faith whether the term of this
Agreement as set forth in Section 8.1 will apply or be extended in respect of
such new indication.
In the event that, for any reason, the Product Committee cannot agree
as to whether or not the Product should be developed for a new indication and
one party but not the other would nevertheless like to pursue
CONFIDENTIAL TREATMENT REQUESTED.
6
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
that indication, the parties will negotiate the terms under which that
indication may be pursued and the Product could be developed and commercialized
in the Territory for that indication. In so doing, the parties agree as
follows:
(i) In the event that Centocor independently proceeds to develop the
Product for such indication it shall notify Schering-Plough upon successful
completion of the first Phase IIb clinical trial establishing proof of efficacy
for the Product for such indication. Schering-Plough shall have [*] days from
the date of such notice in which to acquire the rights to such indication in the
Territory by reimbursing Centocor for [*] of its out-of-pocket costs for
development of such indication, whereupon the parties shall continue the
development and commercialization of such indication under this Agreement. If
Schering-Plough does not acquire the rights to such indication in the Territory,
Centocor or one or more third parties designated by Centocor shall have
exclusive rights to sell the Product for such indication in the Territory but
only if it is a different formulation or in a different dosage form than the
Product the parties are selling under this Agreement and if it is sold under a
separate and distinct trademark from that used for the Product in the Territory
by Schering-Plough under this Agreement; and Centocor and such third party or
third parties shall retain one hundred percent (100%) of the Product revenue
derived from such new indication.
(ii) In the event that Schering-Plough independently proceeds to
develop the Product for such indication it shall notify Centocor upon successful
completion of the first Phase IIb clinical trial establishing proof of efficacy
for the Product for such indication. Centocor shall have [*] days from the date
of such notice in which to notify Schering-Plough of its intent to share
Contribution Income in the Territory and shall reimburse Schering-Plough for [*]
of its out-of-pocket costs for development of such indication, whereupon the
parties shall continue the development and commercialization of such indication
under this Agreement. If Centocor does not provide such notice to Schering-
Plough, Schering-Plough may sell the Product for such indication in the
Territory only if it is a different formulation or in a different dosage form
than the form of the Product the parties are selling under this Agreement and if
it is sold under a separate and distinct trademark from that used for the
Product in the Territory by Schering-Plough under this Agreement; and Schering-
Plough shall retain one hundred percent (100%) of the Product revenue derived
from such new indication. If Schering-Plough proceeds to develop and sell the
Product for such new indication, it shall purchase its requirements of Product
for the clinical development and commercial sales for such new indication from
Centocor, [*], and subject to Centocor's ability to manufacture the Product for
such purposes.
CONFIDENTIAL TREATMENT REQUESTED.
7
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
2.2 SCHERING-PLOUGH'S COMMERCIALIZATION EFFORTS WITH RESPECT TO THE
---------------------------------------------------------------
PRODUCT.
-------
(a) Within the Territory, as to all indications for which Marketing
Approval has been obtained, Schering-Plough will market, promote, distribute and
sell the Product in accordance with the applicable Country Marketing Plans (as
described in Section 4.2) and in a manner consistent with accepted business
practices and applicable legal requirements. For purposes of this Agreement,
promotion includes, but is not limited to, sales presentations to prescribing
physicians by sales representatives which include the use of written promotional
materials, presentations at scientific and medical meetings using promotional
materials, and other personal and non-personal efforts. Such promotional
activities, including detailing, will be carried out through Schering-Plough's
sales force, wherever feasible, or third party sales forces contracted by
Schering-Plough, the members of which will have received the necessary training
and support and have the necessary skills and resources to promote the Product.
The number of face-to-face sales presentations by Schering-Plough for the
promotion and detailing of the Product in the countries to which the EMEA
Approval applies shall be consistent with the level of such activities Schering-
Plough would apply to the promotion of its other pharmaceutical products of
comparable commercial status, potential and value in such countries. In
promoting and detailing the Product, Schering-Plough shall present the Product
in the primary position for the approved indication(s), (i.e., Crohn's Disease
and/or rheumatoid arthritis) until the commercial launch by Schering-Plough of
another product for substantially the same indication(s) developed by Schering-
Plough alone or in conjunction with a third party licensor, licensee or
collaborator, including, without limitation Interleukin-10 (hereinafter a
"Schering-Plough Product"). Commencing with the commercial launch of a
Schering-Plough Product, to the extent that the approved indications and patient
populations for the Product and such Schering-Plough Product overlap, Schering-
Plough shall devote an [*] share of primary details and support, marketing and
promotion to the Product and the Schering-Plough Product in the Territory.
Activities performed by Schering-Plough with respect to the Product pursuant to
this Section, including detailing, advertising and other promotional support,
will in any case be consistent with the level of effort Schering-Plough would
ordinarily employ for a product with similar market potential, commercial value
and status. Centocor shall have the right to audit Schering-Plough's internal
call reporting records to ascertain compliance with this Section. Such audit
shall be conducted in the manner set forth in Section 2.2(d).
(b) In the event that Schering-Plough fails to meet its diligence
obligations under Section 2.2(a) then Centocor shall have the right to give
Schering-Plough written notice thereof stating in reasonable detail the
CONFIDENTIAL TREATMENT REQUESTED.
8
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
particular failure. Schering-Plough shall have a period of [*] days from the
receipt of such notice to correct the failure. Schering-Plough shall, within
[*] days of its receipt of such failure notice from Centocor, provide written
notice to Centocor setting forth: (i) the steps Schering-Plough is undertaking
to cure such failure; or (ii) Schering-Plough's intention to dispute the
allegation that it has failed to meet its diligence obligations. If Schering-
Plough fails to correct the failure, Centocor shall have the right to terminate
this Agreement. In the event of a dispute as to whether or not Schering-Plough
has failed to exercise due diligence under Section 2.2(a), such dispute shall be
resolved through binding arbitration in accordance with the terms of this
Agreement. The time periods set forth in this Section 2.2(b) shall be suspended
during the pendency of such arbitration proceedings.
(c) The foregoing obligations of Schering-Plough with respect to
development and commercialization of the Product are expressly conditioned upon
the continuing absence of adverse conditions or events which, in the aggregate,
warrant a delay in commercialization of the Product including, but not limited
to, an adverse condition or event relating to safety or efficacy, or unfavorable
pricing, pricing reimbursement, labeling or lack of Regulatory Approval.
Schering-Plough's obligation to develop and market the Product shall be delayed
or suspended so long as in the mutual agreement of the parties any such
condition or event exists.
(d) Schering-Plough represents and warrants, on behalf of itself and
its Affiliates, with respect to Germany, France, Italy, Spain and the United
Kingdom, that the personnel responsible for the performance of its diligence
obligations hereunder with respect to the Product in such markets shall
constitute a distinct and separate business unit from those personnel who belong
to the business unit involved in the development and commercialization of
Schering-Plough's [*] product(s). For purposes of this Section 2.2(d), the term
"business unit" shall refer to the sales personnel, product management staff and
support staff responsible for the commercialization of the Product or Schering-
Plough's [*] products, as appropriate. In those countries in the Territory in
which Schering-Plough does not maintain separate business units, Schering-Plough
shall use diligent efforts to ensure that its field sales force and medical
affairs personnel engaged in marketing and promoting [*] do not market and
promote the Product. Schering-Plough and its Affiliates shall keep complete and
accurate records of its operations in sufficient detail to enable Centocor to
confirm the separation of its Product operations from those relating to [*].
Upon forty-five (45) days prior written notice from Centocor, Schering-Plough
shall permit a firm of independent auditors of nationally recognized standing
selected by Centocor and reasonably acceptable to Schering-Plough, at Centocor's
expense, to have access during normal business hours to examine pertinent
records and facilities of Schering-Plough and/or its
CONFIDENTIAL TREATMENT REQUESTED.
9
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
Affiliates as may be reasonably necessary to confirm the separation of Schering-
Plough's Product and [*] operations. An examination under this Section 2.2(d)
shall not occur more than once in any calendar year. Schering-Plough may
designate competitively sensitive information which such auditors may not
disclose to Centocor, provided, however, that such designation shall not
encompass the auditor's conclusions. The auditors shall disclose to Centocor
only whether Schering-Plough's representations with respect to its operations
are correct or incorrect and the specific details concerning any discrepancies.
No other information shall be provided to Centocor. All such auditors shall
sign a confidentiality agreement (in form and substance reasonably acceptable to
Schering-Plough) as to any of Schering-Plough's or its Affiliates' confidential
information which they are provided, or to which they have access, while
conducting any audit pursuant to this Section 2.2(d).
2.3 CHANGE IN TERRITORY.
-------------------
(a) [*]
(b) In the case that Centocor decides to seek an arrangement with
another party for co-promotion of the Product in the United States for
rheumatoid arthritis indications, Centocor will immediately notify Schering-
Plough. Schering-Plough's United States Affiliate, Schering Corporation, will
then have the exclusive right to negotiate with Centocor for a [*] month period
commencing with the date of Centocor's notification to Schering-Plough of the
terms and conditions (including payments upon execution of any agreement) upon
which Schering Corporation would acquire such rights. In the event no agreement
on commercial terms is reached within such period, Centocor will be free to
enter into an agreement with another party to co-promote the Product in the
United States for rheumatoid arthritis, provided that the terms thereof shall be
no less favorable to Centocor than those last offered by Centocor to Schering
Corporation.
2.4 NON-COMPETE. During the term of this Agreement, and for a period
-----------
of [*] years immediately following the termination of this Agreement, Schering-
Plough will not promote, market, manufacture, sell or distribute any [*], other
than the Product or an Improvement, in the Territory; provided, however, that in
the case of any country within the European Union or European Free Trade area,
this obligation not to compete shall cease upon termination of this Agreement.
If Schering Corporation commences to co-promote the Product in the United States
pursuant to either Section 2.1(c) or Section 2.3(b) herein, the terms of this
Section 2.4 thereafter shall be applicable to Schering Corporation in the United
States. The parties acknowledge that during the term of this Agreement,
Schering-Plough may
CONFIDENTIAL TREATMENT REQUESTED.
10
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
promote, market, manufacture, sell and distribute Interleukin-10 in the
Territory.
ARTICLE III
PAYMENTS BY SCHERING-PLOUGH TO CENTOCOR
---------------------------------------
3.1 PAYMENTS UPON EXECUTION. Schering Plough will make a non-
-----------------------
refundable payment of [*] to Centocor by wire transfer within ten (10) business
days of the Effective Date.
(a) Twenty million dollars ($20,000,000) of such payment will be
in recognition of [*].
(b) [*] of such payment will be in recognition of [*].
3.2 ADDITIONAL PAYMENT. Schering-Plough will make an additional
------------------
payment of [*] to Centocor by wire transfer on or before [*].
3.3 MILESTONE PAYMENTS. Schering-Plough will pay to Centocor the
------------------
following non-refundable additional amounts, in each instance by wire transfer
within twenty (20) days of Centocor providing written notification of the
Product Committee's determination of the occurrence of the event which triggers
the payment and an invoice to Schering-Plough:
[*]
ARTICLE IV
COMMITTEES AND MARKETING PLANS
------------------------------
To facilitate the achievement of their commercialization objectives,
the parties agree as follows.
4.1 COMMITTEES. Within thirty (30) days following the Effective
----------
Date, the parties will establish a Product Committee and an Oversight Committee.
(a) PRODUCT COMMITTEE. The Product Committee shall have overall
-----------------
responsibility to monitor, coordinate and oversee the parties' activities
relating to the Product in the Territory, including, without limitation,
CONFIDENTIAL TREATMENT REQUESTED.
11
the specific responsibilities set forth in Sections 4.1(a)(i) and 4.1(a)(ii).
Each party will appoint three (3) representatives to the Product Committee, or
such greater number as the Product Committee may determine from time to time;
provided that two (2) representatives from each party shall constitute a quorum.
These representatives shall have appropriate technical credentials and
knowledge, and shall be senior representatives selected from each of the
following areas: clinical development, marketing/general management and
regulatory. Each party from time to time may substitute one or more of its
representatives, in its sole discretion, effective upon notice to the other
party of such change. The Product Committee may from time to time and in its
sole discretion create ad hoc sub-committees and delegate certain aspects of its
responsibilities to such sub-committees.
The Product Committee will meet on a quarterly basis, or more
frequently if necessary, at mutually agreeable times and locations, to discuss
any matters or issues involving the Product, including, but not limited to,
matters arising under Sections 4.1(a)(i) and 4.1(a)(ii), the manufacture of the
Product and the ways and means of most effectively implementing this Agreement.
The Product Committee shall be co-chaired by a representative of Centocor and a
representative of Schering-Plough. The Co-Chairpersons shall be responsible for
calling meetings, preparing agendas and preparing and issuing minutes of each
meeting within thirty (30) days thereafter. Meeting minutes will be
countersigned by a Product Committee representative from each of Schering-Plough
and Centocor. All decisions of the Product Committee shall be made with a
quorum of the members present, and shall be based on an unanimous vote with
Schering-Plough and Centocor each having one (1) vote.
Additional non-voting representatives or consultants may from time to
time be invited by either party to attend and participate in Product Committee
meetings (e.g., to evaluate and advise on business or scientific issues). Each
party shall ensure that any of its third party consultants attending a Product
Committee meeting have entered into a suitable agreement containing
confidentiality and non-use provisions substantially the same as those contained
in this Agreement.
In September or October of each Agreement Year, the Product Committee
will hold an annual planning meeting to review and comment on the Country
Marketing Plans, and to approve the clinical development plans and the budget
for the following year. If at any time agreement is not reached within the
Product Committee, the matter in question will be referred to the Oversight
Committee should either party deem it to be of sufficient importance to warrant
a further effort to reach agreement.
12
(i) CLINICAL DEVELOPMENT AND REGULATORY APPROVALS. Centocor
---------------------------------------------
will have primary responsibility for the conduct of pre-clinical studies,
clinical trials and regulatory submissions. Nevertheless, the Product Committee
will review and discuss the Product's clinical and regulatory development
including, but not limited to, the design and implementation of clinical trials,
budgets, the content and status of regulatory filings and approvals, and Adverse
Event Reports. Communications between the parties concerning such matters will
be directed through the parties' representatives to the Product Committee or
their designees.
(ii) MARKETING. Subject to Section 2.1(c), the Product
----------
Committee will also discuss indications for which Regulatory Approvals will be
sought, the countries in which Regulatory Approval will be sought, and the
promotion, detailing, marketing, distribution and sales of the Product
including, but not limited to, the Country Marketing Plans and selected core
Marketing Materials (hereinafter defined). Communications between the parties
concerning such matters will be directed through the parties' representatives to
the Product Committee or their designees.
(b) OVERSIGHT COMMITTEE/DISPUTE RESOLUTION. The parties will also
--------------------------------------
establish an Executive Oversight Committee (the "Oversight Committee")
consisting of two (2) senior management representatives of each party. The
initial representatives of the Oversight Committee will be:
Centocor Schering-Plough
-------- ---------------
Xxxxxx X. Xxxxxxx Xxxxxx X. Xxxxx
Xxxxxx X. Xxxxxxx, M.D. Xxxxxxxx X. Xxxxxxxxxxxx, M.D.
The Oversight Committee will meet as necessary, but no less than one time per
year at mutually agreeable times and locations to discuss strategic issues of
interest to the parties and to resolve disputes arising under this Agreement,
including those referred to it by the Product Committee. Decisions by the
Oversight Committee will be made by the unanimous consent of its members. In
the event that the Oversight Committee fails to resolve any dispute, then either
party may submit such dispute to binding arbitration in accordance with the
terms of Section 12.7.
4.2 MARKETING PLANS. Schering-Plough will prepare Country Marketing
---------------
Plans for each country (or, where appropriate, groups of countries) within the
Territory substantially in the form set forth in Appendix D (the "Country
Marketing Plans"), and will present the Country Marketing Plans for the United
Kingdom, Canada, Germany, France, Italy and Spain, as well as the Schering-
Plough Strategic Marketing Plan, to the Product Committee for comment. Each
Country Marketing Plan will establish the strategy and tactics
13
designed to maximize Commercial Sales in that country or group of countries. To
enable Schering-Plough to coordinate its marketing efforts in the Territory,
Centocor will present information regarding its U.S. marketing plans to the
Product Committee, provided, however that Schering-Plough may not provide any of
such information to any line management (excluding executive management)
employee of Schering Corporation or any of its Affiliates who are engaged in any
effort relating to the commercialization of Interleukin-10 in the United States.
4.3 MARKETING AND PROMOTIONAL MATERIALS; TRADEMARKS; LABELS.
-------------------------------------------------------
(a) MARKETING MATERIALS. Schering-Plough will have primary
-------------------
responsibility for the preparation of all Product marketing and promotional
materials (collectively, the "Marketing Materials") for use in the Territory.
However, selected core Marketing Materials, i.e., those prepared by or on behalf
of Schering-Plough's Global Marketing group for use throughout the Territory,
will be submitted to the Product Committee for its review and comment.
Schering-Plough acknowledges that Centocor, as the license holder, is
responsible for regulatory compliance as it relates to all aspects of the
Product, including compliance with regulations relating to promotional
materials. Notwithstanding this fact, under the terms of this Agreement,
Centocor assigns responsibility to Schering-Plough to ensure that its local
Affiliates are in compliance with all local laws and regulatory requirements
governing promotional materials in the Territory. In addition, for the United
Kingdom, Canada, Germany, France, Italy and Spain, Schering-Plough will provide
copies of primary sales aids and journal advertisements intended for use in
these markets to Centocor's regulatory affairs department for its review and
approval as to their compliance with regulatory requirements. Centocor will
review and approve these marketing materials in a timely manner (generally not
to exceed three (3) business days). Schering-Plough indemnifies Centocor for
any damages resulting from regulatory non-compliance in those circumstances
where Centocor's regulatory affairs department has not undertaken a prior
review. Centocor retains the right to audit Schering-Plough's compliance with
local laws and regulations regarding promotion. Such audit shall be conducted
in the manner set forth in Section 2.3(d).
(b) TRADEMARKS. Centocor has applied for the AVAKINE trademark for
----------
the Product in the United States and in certain countries in the Territory (the
"Trademark"). Centocor shall be responsible for filing, prosecuting,
registering, maintaining and protecting the Trademark in all countries in the
Territory. Schering-Plough recognizes that the Trademark is a trademark of
Centocor and that Schering-Plough has no right
14
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
or interest in the Trademark other than those rights explicitly granted in this
Agreement. Centocor hereby grants to Schering-Plough the royalty-free right,
exclusive even as to Centocor, to use during the term of this Agreement, the
Trademark in the Territory for the purpose of co-promoting, marketing, selling
and distributing the Product purchased by Schering-Plough from Centocor under
the terms of this Agreement. To the extent that Schering-Plough is processing,
packaging and labeling the Product pursuant to Section 5.1, Centocor further
grants to Schering-Plough the right to use the Trademark for the purpose of
processing, packaging and labeling the Product for use in the Territory. If
Centocor commences co-promotion of the Product in the Core Co-promotion
Territory and any other countries in the Territory pursuant to Section 2.1(b),
Schering-Plough shall grant back to Centocor the right to use the Trademark in
those countries for the purposes of co-promoting the Product. All rights of
Schering-Plough under this Section will terminate immediately upon the
termination or expiration of this Agreement.
When packaged for sale in the Territory, the Product will bear the
Trademark, the Schering-Plough trade dress and the name and/or logo of the
appropriate Schering-Plough local entity as permitted under applicable laws and
regulations. Schering-Plough will assist Centocor as may be necessary
(including by executing any necessary documents) in recording Schering-Plough as
a licensee of any registration of the Trademark and Schering-Plough hereby
agrees that such recording may be cancelled by Centocor on termination of this
Agreement for whatever reason and that it will assist Centocor to the extent
reasonably necessary to achieve such cancellation including by executing any
necessary documents.
In the event that the Trademark cannot be used in one or more
countries in the Territory, or if it is agreed by the Product Committee that a
different trademark is to be used other than or in addition to the Trademark in
any country in the Territory, then the parties shall agree on a trademark and
Centocor shall determine the availability and shall diligently file for and
prosecute such trademark, which shall thereafter be treated as the Trademark for
the purposes of this Agreement. If the trademark selected by the parties is
already owned by Schering-Plough, then the parties shall enter into a suitable
agreement pursuant to which Schering-Plough shall assign all of its rights,
title and interest in and to said trademark to Centocor in return for a payment
of [*]. If the trademark is acquired from a third party, then Centocor shall be
responsible for acquiring said trademark.
(c) LABELS. When offered for sale in the Territory, the Product will
------
be packaged with Schering-Plough trade dress and, to the extent permitted by
local regulatory requirements, will include the Schering-Plough logo and/or name
of the appropriate Schering-Plough local entity. The
CONFIDENTIAL TREATMENT REQUESTED.
15
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
labeling will state that the Product is manufactured by or on behalf of
Centocor. Where permissible, such labels will give equal prominence to the
Centocor and Schering-Plough names.
ARTICLE V
SUPPLY OF PRODUCT
-----------------
5.1 PURCHASE AND SUPPLY. Centocor agrees to supply to Schering-
-------------------
Plough, and Schering-Plough agrees to purchase from Centocor all of Schering-
Plough's requirements of the Product for Commercial Sales. Centocor further
agrees to supply all quantities of Product for use as free samples or for
compassionate use programs in the Territory, which quantities shall be provided
to Schering-Plough by Centocor [*].
Product supplied by Centocor to Schering-Plough for Commercial Sales
will be in final labelled and packaged vials. Alternatively, Schering-Plough
shall have the option, exercisable by providing written notice to Centocor, to
purchase its requirements for Product from Centocor in the form of bulk Product
and to perform the final processing, packaging and labeling of such material
into finished Product for Commercial Sales in the Territory. Such option shall
only be exercisable by Schering-Plough if Schering-Plough can reasonably
demonstrate that the parties will enjoy a net financial benefit or that it is
cost neutral to the parties for Schering-Plough to perform such activities. If
Schering-Plough exercises its option to perform such activities, Schering-
Plough's cost of performing such activities will be included in [*] as if
Centocor had incurred such costs and delivered finished Product to Schering-
Plough.
Within ninety (90) days of the Effective Date, the parties will
negotiate and enter into a separate Manufacture and Supply Agreement more fully
setting forth the terms under which Product will be manufactured for and
supplied to Schering-Plough by Centocor, the terms of which shall conform to the
terms of this Agreement. The Manufacture and Supply Agreement will be appended
to this Agreement as Appendix E.
5.2 MANUFACTURING. Centocor will manufacture the Product and use
-------------
diligent efforts to satisfy Schering-Plough's requirements for the Product. All
Product manufactured for Schering-Plough for use and/or sale in the Territory
shall be manufactured in an approved facility. Centocor shall provide to
Schering-Plough, concurrently with each shipment of Product supplied to
Schering-Plough under this Agreement (whether in the form of finished Product or
in bulk) a Certificate of Analysis setting forth the
CONFIDENTIAL TREATMENT REQUESTED.
16
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
analytical results and specifications for the batch. In order to ensure the
required supply of Product for sale pursuant to this Agreement, Centocor may
contract with a third party acceptable to Schering-Plough to manufacture the
Product.
In the event that Schering-Plough elects to exercise its option under
Section 5.1 to purchase the Product in bulk, Centocor shall cooperate with and
provide reasonable assistance to Schering-Plough, at Schering-Plough's expense,
to make available to Schering-Plough any Product specific know-how necessary to
enable Schering-Plough to perform the final processing and packaging of the
Product in its facilities and to obtain any necessary regulatory or
manufacturing approvals for such facilities.
5.3 FORECASTS. Beginning on a date to be determined by the Product
---------
Committee and within [*] business days following the end of each calendar
quarter thereafter during the term of this Agreement, Schering-Plough will
supply to Centocor, for planning purposes, a non-binding [*] month rolling
forecast of projected requirements in units of Product for Commercial Sales in
the Territory broken down by country or groups of countries. The forecast may
be expressed in terms of a reasonable range. Centocor will promptly notify
Schering-Plough if it anticipates that it will be unable to meet any portion of
the forecasted requirements. In the event of a temporary shortfall, Centocor's
available supplies of Product will be allocated proportionately according to
Centocor's forecasted demand for the United States on one hand and Schering-
Plough's forecasted demand for the Territory on the other hand. The allocation
will be monitored by the Product Committee and will end as soon as supply
permits.
5.4 FIRM ORDERS; INVENTORY LEVELS. Schering-Plough will provide
-----------------------------
orders for Product to Centocor at least [*] days prior to requested date of
shipment. Schering-Plough will consolidate the orders for itself and its
Affiliates. Within fourteen (14) days of receipt of an order, Centocor will
send to Schering-Plough a written confirmation of such order, at which point
such order will be binding upon Schering-Plough and Centocor. In determining
the amount of its orders, Schering-Plough will order such quantities as are
necessary to maintain at all times a minimum inventory of Product sufficient to
fulfill Schering-Plough's next [*] months expected requirements of the Product
for Commercial Sales. Centocor will use all reasonable efforts to ensure
dispatch to Schering-Plough of the requisite quantity of Product to fulfill such
orders.
5.5 TERMS. All shipments of Product to Schering-Plough will be
-----
F.C.A. (Incoterms 1990) Centocor's place of shipment, by an approved carrier
selected from a list of approved carriers to be agreed upon
CONFIDENTIAL TREATMENT REQUESTED.
17
from time to time by Schering-Plough and Centocor. Shipments will be made to
such locations as Schering-Plough directs. Payment terms will be net thirty
(30) days, upon receipt of Centocor's invoice, in United States Dollars by wire
transfer to Centocor.
5.6 PRODUCT RECALL. Schering-Plough will review with Centocor the
--------------
Schering-Plough product recall procedures and Schering-Plough agrees to maintain
and to implement the same, subject to the provisions herein. Schering-Plough
and Centocor have the responsibility to notify each other within twenty-four
(24) hours of a situation which could lead to a recall or withdrawal of the
Product in the Territory. Within forty-eight (48) hours after such notice, the
parties' representatives from business, medical, regulatory, quality assurance
and legal functions, and any others deemed necessary (the "Recall Team"), will
consult to determine if any Product shall be withdrawn or recalled from the
market. If the Recall Team agrees to conduct a recall, then the Recall Team
shall also consult with respect to the timing of the recall, the breadth, extent
and level of customer to which the recall shall reach, and what strategies and
notifications should be used. If agreement as to whether a recall should be
conducted cannot be reached between the Schering-Plough and Centocor
representatives on the Recall Team, the Oversight Committee shall be immediately
consulted. If the Oversight Committee cannot agree, then the party holding the
marketing authorizations for the Product in the Territory shall have final
decision making authority with respect to any recall in the Territory and
Centocor shall have final decision making authority with respect to countries
outside the Territory. The license holder for the Product will be responsible
for formal notification of the regulatory authorities; however, Centocor and
Schering-Plough will coordinate with each other on the notification of
regulatory authorities. In the Territory, Schering-Plough will be responsible
to implement any Product withdrawal or recall from the market.
(a) In the event that any Product recall or withdrawal occurs in the
Territory as a result of adverse event or other safety reasons for which neither
Centocor nor Schering-Plough are at fault, the parties shall share equally all
reasonable costs and expenses of such Product recall or withdrawal in the
Territory, including, without limitation, the expenses incurred for the
investigation, notification, regulatory reporting, destruction and/or return of
the recalled Product, the cost of the manufactured Product recalled, Schering-
Plough's costs relating to the testing, packaging, shipping and supplying the
Product recalled, expenses or obligations to third parties, and the cost of
notifying users (hereinafter the "Recall Expenses"). For purposes of
calculating Recall Expenses under this Section 5.6(a) and under Sections 5.6(b)
and (c), Centocor shall issue a credit to Schering-Plough for the full cost paid
by Schering-Plough to Centocor for the manufactured Product recalled, and that
cost of the manufactured Product recalled shall be included in Recall
18
Expenses at Centocor's cost of goods. Centocor and Schering-Plough each
acknowledge that the obligations of the other under this Section do not extend
to expenses or obligations of either to third parties or to any claim by either
for loss of anticipated profits, goodwill, reputation, business receipts or
contracts, or losses or expenses resulting from third party claims or for any
indirect or consequential losses suffered by either, howsoever caused, and each
hereby waives any claim to such expenses or losses or which may arise as a
result of any such obligations.
(b) In the event that any Product recall occurs as a result of (i) a
breach of this Agreement by Centocor, or (ii) any wrongful act or omission
whether negligent or otherwise of Centocor, Centocor will bear all reasonable
Recall Expenses incurred by Schering-Plough. Recall Expenses under this Section
5.6(b) shall be calculated as set forth in Section 5.6(a). Schering-Plough
acknowledges that Centocor's obligations under this Section do not extend to
expenses or obligations of Schering-Plough to third parties or to any claim by
Schering-Plough for loss of anticipated profits, goodwill, reputation, business
receipts or contracts, or losses or expenses resulting from third party claims
or for any indirect or consequential losses suffered by Schering-Plough,
howsoever caused, and hereby waives any claim to such expenses or losses or
which may arise as a result of any such obligations.
(c) In the event that any Product recall occurs as a result of (i) a
breach of this Agreement by Schering-Plough, or (ii) any wrongful act or
omission, whether negligent or otherwise of Schering-Plough, Schering-Plough
will bear all reasonable Recall Expenses incurred by Centocor. Recall Expenses
under this Section 5.6(c) shall be calculated as set forth in Section 5.6(a).
Centocor acknowledges that Schering-Plough's obligations under this Section do
not extend to expenses or obligations of Centocor to third parties or to any
claim by Centocor for loss of anticipated profits, goodwill, reputation,
business receipts or contracts, or losses or expenses resulting from third party
claims or for any indirect or consequential losses suffered by Centocor,
howsoever caused, and hereby waives any claim to such expenses or losses or
which may arise as a result of any such obligations.
5.7 PRODUCT WARRANTIES. Centocor warrants good title to the Product
------------------
and warrants that upon delivery of Product in accordance with this Agreement,
the Product:
(a) will have been manufactured, stored and shipped in accordance with
all applicable good manufacturing practices, all other applicable laws, rules,
regulations and regulatory requirements in the country
19
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
of manufacture and in the Territory, and will conform to the specifications set
forth in Appendix F;
(b) shall not be adulterated or misbranded as provided for under any
applicable law, order or regulation in effect in the country of manufacture and
the Territory;
(c) shall conform to the specifications for the Product in the then
current Regulatory Approvals of each country in the Territory;
(d) shall, when stored at [*], have a shelf life of at least [*]
months from the completion of lyophilization and shall be delivered within
ninety (90) days of the completion of lyophilization; and
(e) will be labeled, packaged and shipped in accordance with labeling,
packaging and distribution standards mutually agreed upon by the parties and in
accordance with all applicable laws and regulatory requirements in the
Territory; provided that where Schering-Plough is responsible under the terms of
this Agreement for obtaining any Regulatory Approval, any requirements for
labeling and packaging of the Product specified in such approvals have been
fully communicated to Centocor.
EXCEPT FOR THE FOREGOING WARRANTIES, CENTOCOR MAKES NO OTHER
WARRANTIES AS TO THE PRODUCT, EITHER EXPRESS OR IMPLIED, AND
SPECIFICALLY, MAKES NO IMPLIED WARRANTY AS TO MERCHANTABILITY OR
FITNESS FOR A PARTICULAR PURPOSE.
5.8 INSPECTION AND RIGHT OF RETURN OF PRODUCT. If Schering-Plough
-----------------------------------------
determines upon receipt and inspection of the Product that any of the Product
does not meet any of the standards warranted in Section 5.7, Schering-Plough
will notify Centocor of the non-conformance within forty-five (45) days of
receipt of shipment; provided, however, that if the defect is a Hidden Defect,
Schering-Plough will notify Centocor of the non-conformance within fifteen (15)
days of Schering-Plough's discovery of the defect. Centocor and Schering-Plough
will confer on the matter and, within fifteen (15) days after receipt of
Schering-Plough's notice, Centocor will notify Schering-Plough as to whether or
not it concurs with Schering-Plough's determination. If Centocor concurs with
Schering-Plough's determination (or fails to timely notify Schering-Plough of a
disagreement with the determination), Centocor will replace the rejected
Product, free of charge, as
CONFIDENTIAL TREATMENT REQUESTED.
20
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
soon as practicable thereafter, and in any event within forty (40) days after
receipt of Schering-Plough's notice, and Schering-Plough will, at Centocor's
request and expense, return the rejected Product. If Centocor timely disagrees
with Schering-Plough's determination, the parties will attempt to resolve the
issue in accordance with the provisions of Section 4.1(b). If Schering-Plough
does not provide a notice of non-conformance within forty-five (45) days of
receipt of shipment (or within fifteen (15) days after Schering-Plough's
discovery of a Hidden Defect), Schering-Plough will not have the right to return
the shipment pursuant to this Section. Except as set forth in this Section and
in Section 5.7 and Section 10.1, Centocor will have no obligation to Schering-
Plough for breach of any of the warranties as to the quality of the Product set
forth in Section 5.7. For purposes of this Section, "Hidden Defect" means a
defect which prevents use of the Product for its normal application and which
could not have been discovered by Schering-Plough upon routine inspection
following its receipt of the Product.
ARTICLE VI
PAYMENTS BASED ON SALES; OTHER PAYMENTS
---------------------------------------
6.1 CENTOCOR SALES TO SCHERING-PLOUGH. The parties estimate that the
---------------------------------
initial price per vial will be [*] of the forecasted average Schering-Plough net
selling price for sales of the Product in the Territory, which forecasted
average net selling price will be determined by Schering-Plough and will be
communicated to Centocor by Schering-Plough. From time to time the Product
Committee will review the transfer price and adjust it as necessary. For this
purpose, the unit at the outset of Commercial Sales is a vial containing one
hundred milligrams (100 mg) of active ingredient Product.
6.2 DIVISION OF CONTRIBUTION INCOME. The parties will divide
-------------------------------
Contribution Income in the manner provided herein and in Section 2.1(b).
(a) "Contribution Income" is defined as [*].
(i) A list of third party agreements providing for the
payment of royalties, as of the Effective Date, is attached as Appendix G. [*].
As of the Effective Date, Centocor shall not enter into any other additional
agreements with third parties that include provisions requiring the payment of
license fees, milestones, royalties or other payments relating to
commercialization of Product in the Territory without the prior written approval
of Schering-Plough.
CONFIDENTIAL TREATMENT REQUESTED.
21
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
(ii) For purposes of calculating Contribution Income, [*].
(iii) As set forth in Section 6.3, Product Development Costs
are excluded from Contribution Income. Also excluded from the Contribution
Income calculation is the cost of Product supplied by Centocor to Schering-
Plough in the Territory for distribution as free samples or for compassionate
use programs pursuant to Section 5.1.
(b) For purposes of documenting [*] expenses which are included in
the Contribution Income calculation, each party will maintain adequate and
reasonable records containing information to quantify the activities and costs
and qualify the activities under the programs approved in accordance with
Article IV; and will provide the other party's independent representative access
to such records in accordance with Section 6.4. To enable Centocor to comply
with its quarterly financial reporting obligations, Schering-Plough will provide
to Centocor on a monthly basis no later than ten (10) business days after the
end of each month its actual Net Sales for such month. In addition, Schering-
Plough will provide to Centocor on a quarterly basis no later than fifteen (15)
business days after the end of each calendar quarter, or with respect to the
fourth calendar quarter in any calendar year within thirty (30) days of the last
day of such calendar year, a summary of its actual Net Sales and an estimate of
its [*] expenses for that quarter, and estimates of Net Sales, [*] expenses for
the next calendar quarter.
(c) Contribution Income with respect to any Agreement Year is to
be divided [*] to Schering-Plough and [*] to Centocor on the first [*] of Net
Sales in such Agreement Year. For Net Sales in excess of [*] in each Agreement
Year, Contribution Income is to be divided [*] to Schering-Plough and [*] to
Centocor. An example of the quarterly Contribution Income Calculation is set
forth in Appendix H.
(d) The calculation of Contribution Income will commence at the
time of the first Commercial Sale in the Territory. [*].
(e) The division of Contribution Income will be effected as
follows:
(i) Within [*] days after the end of each calendar quarter (or
portion thereof), the parties will calculate and agree upon the amount of
Contribution Income for that quarter and Centocor will remit to Schering-Plough,
or Schering-Plough will remit to Centocor, upon submission of an invoice, a
quarterly equalization payment within [*] days of receipt of such invoice.
CONFIDENTIAL TREATMENT REQUESTED.
22
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
(ii) If, for any period, the Contribution Income calculation results
in a net loss, the parties will share the loss in the same proportions that they
share Contribution Income.
(iii) Notwithstanding the foregoing, to the extent that Centocor is
co-promoting the Product in one or more countries in the Territory pursuant to
the provisions of Section 2.1(b), then commencing in the calendar quarter of the
Agreement Year in which Centocor begins co-promoting the Product in the
Territory, the division of Contribution Income will be [*] to Schering-Plough
and [*] to Centocor solely with respect to Contribution Income attributable to
Net Sales in the country or countries in which Centocor is co-promoting the
Product.
6.3 PRODUCT DEVELOPMENT COSTS. All Product Development Costs are
-------------------------
expressly excluded from the Contribution Income sharing concept and, subject to
Section 2.1(c) above, shall be shared by the parties as follows.
(a) Subject to variances in patient accrual rates, the parties
agree that the anticipated budget for Product Development Costs in calendar year
1998 shall not exceed [*]. The parties further agree that, subject to variances
in patient accrual rates, the anticipated budget for Product Development Costs
in calendar year 1999 for the clinical trials already in progress or ready to be
started and for the ACCENT study is estimated at [*]. Schering-Plough shall make
a payment of [*] to Centocor by wire transfer on or before [*]. Schering-
Plough's obligation to pay for Product Development Costs incurred during 1998
and 1999 with respect to such studies shall be capped, unless the Product
Committee elects to initiate additional clinical studies during such calendar
years or the Product Committee otherwise approves additional Product Development
Costs to be incurred in such calendar years. To the extent that either party
exceeds the agreed upon budgeted Product Development Costs for such activities
without the prior written approval of the Product Committee, such party shall be
solely responsible for such excess expenditures which shall be excluded from
Product Development Costs.
(b) In each successive Agreement Year after 1999 during the term
of this Agreement, the parties shall agree upon a budget setting forth the
estimated Product Development Costs for their respective development activities.
To the extent that either party exceeds the agreed upon budgeted Product
Development Costs for such activities without the prior written approval of the
Product Committee, such party shall be solely responsible for such excess
expenditures which shall be excluded from the calculation of any Excess Amount
under Section 6.3(c).
CONFIDENTIAL TREATMENT REQUESTED.
23
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
(c) Within thirty (30) days following the end of each calendar
quarter, each party will provide a written summary to the other party of its
respective Product Development Costs for such calendar quarter. Such summary
will include adequate and reasonable information to quantify the activities and
costs and qualify the activities under the programs approved in accordance with
Article IV. With respect to any such calendar quarter, the amount by which the
total of one party's Product Development Costs exceeds the total of the other
party's Product Development Costs is referred to herein as the "Excess Amount,"
and the party whose total Product Development Costs are less than the other
party's total Product Development Costs is referred to herein as the "Paying
Party." Commencing in calendar year 2000, within [*] days following the end of
each calendar quarter, upon submission of an invoice, the Paying Party will pay
to the other party an amount equal to [*] of the Excess Amount for such calendar
quarter.
(d) With respect to calendar years 1998 and 1999 in the aggregate,
Schering-Plough will not be required to pay Centocor unless the Product
Committee has approved spending of total Product Development Costs in excess of
[*] and [*] of the Excess Amount payable by Schering-Plough is greater than [*],
in which event Schering-Plough will pay Centocor the amount by which [*] of the
Excess Amount exceeds [*]. If the total of both parties' Product Development
Costs is [*] or less and [*] of the Excess Amount is less than [*], then (1) if
Schering-Plough would otherwise be the Paying Party as defined above, Schering-
Plough shall make no payment to Centocor and Centocor shall pay Schering-Plough
the amount by which [*] exceeds [*] of the Excess Amount; and (2) if Centocor is
the Paying Party as defined above, Centocor shall pay Schering-Plough [*] plus
[*] of the Excess Amount. The parties will within thirty (30) days after the
end of calendar year 1999 exchange information relating to Product Development
Costs for 1998 and 1999, determine whether any payment is due from one party to
the other party under this Section 6.3(d), and issue an appropriate invoice to
the party owing such payment, if any. Any such payment shall be made within [*]
days after the end of calendar year 1999.
6.4 ACCESS TO INFORMATION. Each party will have the right, upon
--------------------------
forty-five (45) days prior written notice and during normal business hours,
through an independent third party representative (who will agree to be bound by
confidentiality provisions substantially similar to those set forth in Sections
11.1 and 11.2 hereof), to review and inspect the other party's books and records
which relate to such other parties's operations under this Agreement including,
but not limited to, records concerning Commercial Sales, Net Sales, Product
Development Costs, [*], sales presentations, [*], and other costs. The
inspection shall be limited to pertinent books and records for
CONFIDENTIAL TREATMENT REQUESTED.
24
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
any year ending not more than [*] months prior to the date of such request. An
inspection under this Section 6.4 shall not occur more than once in any calendar
year. The party whose records are being inspected may designate competitively
sensitive information which the representative may not disclose to the other
party, provided, however, that such designation shall not encompass the
representative's conclusions. Such representative shall only report
inaccuracies in amounts payable under this Agreement. With respect to
inspection of Schering-Plough's books and records, Schering-Plough may request
that an independent auditor familiar with Schering-Plough's record keeping
systems be present at the inspection to assist Centocor's auditor in using
Schering-Plough's internal record management system. Likewise, with respect to
inspection of Centocor's books and records, Centocor may request that an
independent auditor familiar with Centocor's record keeping systems be present
at the inspection to assist Schering-Plough's auditor in using Centocor's
internal record management system. Each party shall bear the costs and expenses
of its representative for inspections conducted under this Section, unless a
variation or error producing an underpayment in amounts payable exceeding [*] of
the amount paid for any period covered by the inspection is established in the
course of any such inspection, whereupon all costs relating to the inspection
for such period and any unpaid or overpaid amounts that are discovered will be
paid or credited as appropriate by the party in whose favor the deviation
occurred. This Section will survive the expiration or the termination of the
Agreement for a period of two (2) years.
6.5 CURRENCY TRANSLATION. For the purpose of computing the
--------------------
Commercial Sales or Net Sales of Product sold in a currency other than United
States Dollars, for the purpose of computing costs for calculating Contribution
Income where the costs are incurred in a currency other than United States
Dollars, and for the purpose of determining Centocor Product Development Costs
or Schering-Plough Product Development Costs which are incurred in a currency
other than United States Dollars, such currency shall be converted into United
States Dollars at the rates of exchange used by Schering Corporation to report
its sales for public, financial reporting purposes. A copy of the current
policy used by Schering-Plough and its Affiliates for bookkeeping exchange rates
is attached hereto as Appendix I. Schering-Plough shall treat the Product in a
manner consistent with its standard practices used for its own products, in
order to minimize foreign currency exposure.
6.6 WITHHOLDING. If at any time, any jurisdiction within the
-----------
Territory requires the withholding of income taxes or other taxes imposed upon
payments set forth in this Article VI, the party required to make such
withholding payment shall make the payment and subtract such withholding
payments from the payments set forth in this Article VI. The party required to
make any such payment shall provide to the other party documentation of such
CONFIDENTIAL TREATMENT REQUESTED.
25
withholding and payment in a manner that is satisfactory for purposes of the
U.S. Internal Revenue Service. Any withholdings paid when due hereunder shall
be for the account of the party liable for such taxes and shall not be included
in the calculation of Net Sales or Contribution Income. Withholding payments
made by either party pursuant to this Section 6.6 shall be made based upon
financial information provided to the party making the payment by the other
party; to the extent that such information is incorrect, the party providing
such information shall be liable for any deficiency, and any fine, assessment or
penalty imposed by any taxing authority in the Territory for any deficiency in
the amount of any such withholding or the failure to make such withholding
payment. If either party is required to pay any such deficiency, or any fine,
assessment or penalty for any such deficiency, the party liable for such payment
shall promptly reimburse the other party for such payment, which shall not be
included in the calculation of Net Sales or Contribution Income.
6.7 FAILURE TO AGREE. In the event the parties fail to agree on any
----------------
payment due from one party to the other under this Agreement, such dispute shall
be resolved in accordance with the provisions of Section 4.1(d).
ARTICLE VII
REGULATORY MATTERS
------------------
7.1 REGULATORY APPROVALS AND CLINICAL STUDIES. Prior to the
-----------------------------------------
Effective Date, Centocor will fully inform Schering-Plough of, and provide full
access to information to Schering-Plough regarding, all Product clinical studies
in progress as of the Effective Date. Following the Effective Date, Centocor
and Schering-Plough, through the Product Committee, will coordinate such in-
progress clinical studies. Centocor and Schering-Plough will, through the
Product Committee, jointly propose, develop and coordinate all clinical studies
for the Product to be initiated after the Effective Date. In some instances,
management of clinical studies may be delegated to Schering-Plough, although
Centocor, as the party responsible for obtaining and maintaining Regulatory
Approvals, will ultimately be responsible for all pre-clinical and clinical
studies. The parties acknowledge their mutual intent that, subject to locally
applicable laws in each country of the Territory, Centocor will hold all
marketing authorizations in its name. Notwithstanding the foregoing, Centocor
shall promptly take all steps necessary to ensure that as of the date of
Marketing Approval in each country in the Territory Schering-Plough shall have
the right to market, promote, distribute, import, export, offer for sale and
sell the Product in the Territory under the Trademark and using Schering-
Plough's trade dress (including, without limitation, the transfer
26
of the relevant marketing authorizations to Schering-Plough and/or its
designated Affiliate, if necessary).
7.2 LICENSES, FILINGS, REGISTRATIONS, PERMITS AND REGULATORY
--------------------------------------------------------
APPROVALS. In collaboration with Schering-Plough, Centocor will be responsible
---------
for obtaining and maintaining all licenses, registrations, permits and any other
required Regulatory Approvals relating to the Product; provided, however, that
Schering-Plough, with Centocor's support, will be responsible for obtaining and
maintaining those licenses, registrations, permits and regulatory approvals
required to be obtained by Schering-Plough to enable Schering-Plough to act as
the exclusive distributor of the Product in the Territory pursuant to this
Agreement. Each of the parties will cooperate with the other in making all
regulatory filings that may be necessary or desirable in connection with the
execution, delivery and performance of this Agreement and each will use all
reasonable efforts to obtain any regulatory approvals related thereto. To
enable Schering-Plough to assist Centocor in obtaining regulatory approvals,
Centocor will provide Schering-Plough access to Centocor's regulatory filing
documentation, with the exception of the manufacturing master file. On
expiration or termination of this Agreement, for whatever reason, Schering-
Plough will use all reasonable efforts to effect the transfer of any such
licenses, registrations, permits or approvals as may be in its name in relation
to the Product to Centocor or such other entity as Centocor may nominate. If
the Agreement is terminated upon Schering-Plough's fault, the cost of such
transfer will be borne by Schering-Plough. If the Agreement is terminated upon
Centocor's fault, the cost of such transfer will be borne by Centocor. In all
other cases the cost will be equally shared by Centocor and Schering-Plough.
7.3 ADVERSE EVENT REPORTING AND DRUG SAFETY INFORMATION. As the
---------------------------------------------------
license holder, Centocor will have ultimate responsibility for adverse event
reporting and drug safety information in the United States and in those
countries in the Territory in which Centocor holds the relevant marketing
authorizations. Schering-Plough shall have such responsibility in those
countries in the Territory where it holds the relevant marketing authorizations
and/or is otherwise required by law to report adverse events. Promptly after
the Effective Date, the drug safety departments of Centocor and Schering-Plough
shall agree upon suitable protocols and procedures to further delineate each
party's obligations with respect to adverse event reporting which shall be
incorporated into a separate written agreement of the parties. (The outline of
such adverse event reporting and drug safety agreement contained in Appendix J
as of the Effective Date will be the basis for finalizing such new agreement,
which new agreement will supersede and replace the outline.) In any event,
during the term of this Agreement, each party will, within the time periods and
in accordance with procedures set forth in Appendix J, notify the
27
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
other party of all information coming into its possession concerning side
effects, injury, toxicity or sensitivity reactions, including unexpected
increased incidence or severity thereof, associated with commercial or clinical
uses, studies, investigations or tests with the Product, inside or outside the
Territory, whether or not determined to be attributable to the Product.
7.4 COMMUNICATION WITH AGENCIES. Centocor, as the party responsible
---------------------------
for obtaining and maintaining Regulatory Approvals, will have the primary
responsibility for communications with various regulatory agencies but will do
so in collaboration with Schering-Plough. Schering-Plough will have the right
to have representatives present at all meetings with regulatory agencies in the
Territory concerning the Product. The foregoing notwithstanding, to the extent
that Schering-Plough holds the market authorizations and Marketing Approvals in
a country in the Territory, Schering-Plough shall have primary responsibility
for such communications, and will do so in collaboration with Centocor, with
Centocor having the right to have representatives present at any meetings with
regulatory agencies in such countries concerning the Product. Each party will
provide the other with copies of any significant communications (which are known
to the party to exist and which the party can obtain copies of) with any
regulatory agency throughout the world concerning the Product, including but not
limited to reports of Adverse Events, but excluding communications pertaining to
or included in the manufacturing master file.
ARTICLE VIII
TERM OF AGREEMENT
-----------------
8.1 TERM. This Agreement is effective on the Effective Date. It
----
will continue for a term of fifteen (15) years from the date of the first
Commercial Sale in the Territory, unless earlier terminated pursuant to the
provisions of this Agreement.
8.2 TERMINATION.
-----------
(a) BREACH OF OBLIGATION. In the event of a material breach of
--------------------
this Agreement by either party, the non-breaching party will give the breaching
party written notice requiring it to remedy such breach. If, after [*] days
following such notice, the breach is neither fully remedied nor a plan to remedy
it has been agreed by the parties, the non-breaching party will, in addition to
having the right to seek an arbitration award under Section 12.7 for any damages
to which it may be entitled, be entitled to terminate this
CONFIDENTIAL TREATMENT REQUESTED.
28
Agreement with immediate effect upon written notice thereof to the breaching
party.
(b) INSOLVENCY. This Agreement may be terminated by either party upon
----------
written notice to the other should the other party (i) become insolvent; or (ii)
file a voluntary petition under any bankruptcy or insolvency law; or (iii) have
any such petition filed against it which is not stayed within sixty (60) days of
such filing; or (iv) has a receiver appointed for its business or property; or
(v) makes a general assignment for the benefit of its creditors. Such
termination shall be made effective the date notice of termination is given. In
the event of Centocor's insolvency, Centocor shall provide to Schering-Plough
access to Centocor's drug master file in order to enable Schering-Plough to
undertake manufacture of the Product.
(c) CHANGE IN CONTROL. If either party is acquired by a third party
-----------------
or otherwise comes under Control (as defined in Section 1.4 above) of a third
party, it will promptly notify the other party not subject to such change of
control. The party not subject to such change of control will have the right,
however not later than thirty (30) days from such notification, to notify in
writing the party subject to the change of Control of the termination of the
Agreement taking effect immediately. As used herein "Change of Control" shall
mean (i) any merger, reorganization, consolidation or combination in which a
party to this Agreement is not the surviving corporation; or (ii) any "person"
(within the meaning of Section 13(d) and Section 14(d)(2) of the Securities
Exchange Act of 1934), excluding a party's Affiliates, is or becomes the
beneficial owner, directly or indirectly, of securities of the party
representing more than fifty percent (50%) of either (A) the then-outstanding
shares of common stock of the party or (B) the combined voting power of the
party's then-outstanding voting securities; or (iii) if individuals who as of
the Effective Date constitute the Board of Directors of the party (the
"Incumbent Board") cease for any reason to constitute at least a majority of the
Board of Directors of the party; provided, however, that any individual becoming
a director subsequent to the Effective Date whose election, or nomination for
election by the party's shareholders, was approved by a vote of at least a
majority of the directors then comprising the Incumbent Board shall be
considered as though such individual were a member of the Incumbent Board, but
excluding, for this purpose, any such individual whose initial assumption of
office occurs as a result of an actual or threatened election contest with
respect to the election or removal of directors or other actual or threatened
solicitation of proxies or consents by or on behalf of a person other than the
Board; or (iv) approval by the shareholders of a party of a complete liquidation
or the complete dissolution of such party.
8.3 EFFECT OF EXPIRATION AND TERMINATION.
------------------------------------
29
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
(a) ACCRUED OBLIGATIONS. Expiration or termination of this Agreement
-------------------
for any reason will not release any party hereto from any obligation and any
liability which, at the time of such expiration or termination, has already
accrued to the other party or which is attributable to a period prior to such
expiration or termination, nor will it preclude either party from pursuing all
rights and remedies it may have hereunder with respect to any breach of this
Agreement.
(b) OUTSTANDING AND NEW ORDERS. Upon delivery of a termination notice
--------------------------
by either party, the parties will seek agreement to what extent outstanding
orders, and whether new orders of Schering-Plough addressed to Centocor, will be
fulfilled. In any case, Centocor acknowledges (i) that Schering-Plough's supply
obligations to its customers will be taken into consideration, and (ii) that
Schering-Plough has no obligation to accept delivery of the Product to the
extent its ability or authority to import, distribute and/or sell the Product
has expired for practical or for legal reasons.
(c) STOCK OF PRODUCT. Upon expiration of the Agreement and upon
----------------
termination of the Agreement by either party for any reason other than a
material breach by Schering-Plough, to the extent that Schering-Plough then
holds in its inventory a quantity of Product the purchase price of which exceeds
the value of Centocor's work-in-process and finished inventory of Product
intended for shipment to Schering-Plough pursuant to firm orders, Centocor will
repurchase or have repurchased by an entity of its choice at the per unit price
paid by Schering-Plough to Centocor according to Section 6.1 and under terms
analogous to Section 5.5, a quantity of Product such that following such
repurchase, the amount paid by Schering-Plough for its remaining inventory of
Product will equal the cost of Centocor's work-in-process and finished inventory
of Product intended for shipment to Schering-Plough pursuant to firm orders;
provided, however, that in no event will Centocor be required to repurchase any
inventory with a remaining shelf life of less than [*] months.
(d) PRODUCT SELL OFF. Upon expiration or termination of this
-----------------
Agreement for any reason, Schering-Plough shall have the right to continue to
sell its existing inventory of Product in the Territory for a period of [*]
months from the effective date of such expiration or termination. The parties
will continue to share the Contribution Income arising from any such sales in
accordance with the terms of this Agreement. If such termination is the result
of a material breach of this Agreement by Centocor, Centocor shall be obligated
to repurchase from Schering-Plough all unsold quantities of Product in Schering-
Plough's inventory, unless Schering-Plough notifies Centocor in writing at the
time of the termination that it elects to sell its existing inventory for a
period of [*] months. If Schering-Plough elects to sell
CONFIDENTIAL TREATMENT REQUESTED.
30
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
its existing inventory following termination due to a material breach of this
Agreement by Centocor, Centocor shall not be obligated to repurchase product
with a shelf life of less than [*] months.
ARTICLE IX
REPRESENTATIONS AND COVENANTS
-----------------------------
9.1 REPRESENTATIONS OF CENTOCOR. Centocor represents and warrants to
---------------------------
Schering-Plough as follows:
(a) ORGANIZATION AND GOOD STANDING. Centocor is a corporation duly
------------------------------
organized, validly existing and in good standing under the laws of the
Commonwealth of Pennsylvania.
(b) AUTHORITY. Centocor has the corporate power to enter into this
---------
Agreement and to carry out the transactions contemplated hereby. The execution,
delivery and performance of this Agreement have been duly and validly authorized
and approved by all necessary corporate action on the part of Centocor and this
Agreement has been duly executed by and constitutes the legally binding
obligation of Centocor, enforceable in accordance with its terms (except that
such enforcement may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium and other similar laws affecting the enforcement of
creditors' rights, as from time to time in effect, and general principles of
equity). The execution and delivery of this Agreement do not, and the
consummation by Centocor of the transactions contemplated hereby will not,
violate the provisions of, constitute a default under or give rise to rights of
any entity under (i) any laws applicable to Centocor, (ii) Centocor's Articles
of Incorporation or bylaws, (iii) any judgment, decree or order of any court or
governmental agency applicable to Centocor or (iv) any agreements, contracts or
commitments to which Centocor is a party.
(c) GOVERNMENTAL CONSENTS. Apart from Regulatory Approvals and except
---------------------
for the subjects addressed in Section 12.15, no consent, approval, order or
authorization of, or registration, qualification, designation, declaration or
filing with, any federal, state or local governmental authority is required in
connection with the consummation by Centocor of the transactions contemplated by
this Agreement.
(d) ACCESS TO DATA. Centocor has provided to Schering-Plough for its
--------------
review all relevant information except certain information relating to the
manufacturing of the Product. Centocor has also
CONFIDENTIAL TREATMENT REQUESTED.
31
provided to Schering-Plough details of all adverse events known to it relating
to the Product.
(e) PATENT INFRINGEMENT. To Centocor's knowledge, there exists no
-------------------
valid and enforceable patent owned by a third party which would prevent: (i)
the use, manufacture or sale of the Product in the United States or the
Territory; or (ii) the import, export, marketing, promotion, distribution,
offering for sale or sale of the Product in the Territory by Schering-Plough
and/or its Affiliates.
(f) CENTOCOR LICENSES. The consummation of the transactions
-----------------
contemplated by this Agreement by Schering-Plough will not require additional
licenses under any third party patent licensed to Centocor.
9.2 CENTOCOR COVENANTS.
------------------
(a) Centocor covenants to Schering-Plough that it will take such
actions as are necessary to enable Schering-Plough to import, export, market,
promote, distribute, use and sell the Product in all countries in the Territory,
as of the date of Marketing Approval in each such country, under the Trademark
and using Schering-Plough's trade dress.
(b) Centocor covenants to Schering-Plough that: (i) it will comply
fully with all laws applicable to Centocor and its activities under this
Agreement; and (ii) it will notify Schering-Plough promptly in writing of any
material civil, criminal or administrative action brought against Centocor, its
directors, officers, employees or agents which is likely to have a material
adverse effect on Centocor's pharmaceutical business or Centocor's business
reputation, or is likely adversely to affect Centocor's ability to perform its
obligations under this Agreement, and promptly to provide Schering-Plough with
reasonably detailed information regarding Centocor's handling and disposition of
any such action; and (iii) except as mutually agreed by the parties, during the
term of this Agreement, it will not enter into any distributorship agreements,
marketing arrangements, licenses or similar arrangements granting any third
party the right to distribute, market, promote or sell the Product in the
Territory.
(c) Centocor covenants to Schering-Plough that it will (i) use
diligent efforts not to diminish the rights under "Patent Rights" held by
Centocor and/or granted to Schering-Plough hereunder or under the License
Agreement attached hereto as Appendix L, including without limitation, by not
committing or permitting any actions or omissions which would cause the breach
of any agreements between itself and third parties which provide for
intellectual property rights applicable to the manufacture, use or sale of the
32
Product, (ii) provide Schering-Plough promptly with notice of any such alleged
breach, and (iii) as of the Effective Date, it is in compliance in all material
respects with any such agreements with third parties. For purposes of this
Section 9.2(c), the term "Patent Rights" shall mean any and all patents and
patent applications (which for the purposes of this Agreement shall be deemed to
include certificates of invention and applications for certificates of
invention) which during the term of this Agreement are owned or controlled by
Centocor (wherein control means the ability to grant licenses and/or
sublicenses) and have claims covering (A) the Product and/or any Improvements,
(B) any materials, methods or processes used in the manufacture of the Product
and/or any Improvements, or (C) any methods of use or new indications for the
Product and/or Improvements, as well as any substitutions, divisions,
continuations, continuations-in-part, reissues, renewals, registrations,
confirmations, re-examinations, extensions, supplementary protection
certificates or the like, of any of the foregoing.
9.3 REPRESENTATIONS OF SCHERING-PLOUGH. Schering-Plough represents
----------------------------------
and warrants to Centocor as follows:
(a) ORGANIZATION AND GOOD STANDING. Schering-Plough is a corporation
------------------------------
duly organized, validly existing and in good standing under the laws of
Switzerland.
(b) AUTHORITY. Schering-Plough has the corporate power to enter into
---------
this Agreement and to consummate the transactions contemplated by this
Agreement. The execution, delivery and performance of this Agreement have been
duly and validly authorized and approved by all necessary corporate action on
the part of Schering-Plough and this Agreement has been duly executed by and
constitutes the legally binding obligation of Schering-Plough enforceable in
accordance with its terms (except that such enforcement may be limited by
applicable bankruptcy, insolvency, reorganization, moratorium and other similar
laws affecting the enforcement of creditors' rights generally, as from time to
time in effect, and general principles of equity). The execution and delivery
of this Agreement by Schering-Plough do not, and the consummation by Schering-
Plough of the transactions contemplated hereby will not, violate the provisions
of, constitute a default under or give rise to rights of any entity under (i)
any laws applicable to Schering-Plough, (ii) the Articles or Certificate of
Incorporation or other charter documents or bylaws of Schering-Plough, (iii) any
judgment, decree or order of any court or governmental agency applicable to
Schering-Plough or (iv) any agreements, contracts or commitments to which
Schering-Plough is a party.
33
(c) GOVERNMENTAL CONSENTS. Except for the subjects addressed in
---------------------
Section 12.15, no consent, approval, order or authorization of, or registration,
qualification, designation, declaration or filing with, any federal, state or
local governmental authority is required in connection with the consummation by
Schering-Plough of the transactions contemplated by this Agreement.
(d) ACCESS TO DATA. In entering into this Agreement, Schering-Plough
--------------
is relying solely upon its independent investigation of Centocor's business and
its independent consultation with such professional, legal and accounting
advisors as it deems necessary, and is not acting in reliance on any statements,
instruments, certificates, documents, representations or warranties other than
those contained or referred to in this Agreement.
9.4 SCHERING-PLOUGH COVENANTS. Schering-Plough covenants to Centocor
-------------------------
that it will: (i) comply fully with all laws applicable to Schering-Plough and
its activities under this Agreement; (ii) notify Centocor promptly in writing of
any material civil, criminal or administrative action brought against Schering-
Plough, its directors, officers, employees or agents which is likely adversely
to affect Schering-Plough's ability to perform its obligations under this
Agreement, and promptly to provide Centocor with reasonably detailed information
regarding Schering-Plough's handling and disposition of any such action; and
(iii) except as provided in Section 7.2, not initiate any voluntary
communications with regulatory agencies relating to the Product without
Centocor's prior consent.
ARTICLE X
INDEMNIFICATION AND INSURANCE
-----------------------------
10.1 CENTOCOR INDEMNIFICATION. Centocor will defend and indemnify
------------------------
Schering-Plough, its Affiliates and their respective directors, officers,
employees and agents against all claims, losses, damages, liabilities, and
expenses, including reasonable attorneys' fees (collectively "Losses") arising
out of or resulting from: (i) any product liability or similar claim relating
to the Product (except to the extent any such Losses are caused by the
negligence, willful misconduct or illegal acts of Schering-Plough); (ii) any
other claim relating to the Product to the extent such Losses are caused by the
negligence, willful misconduct or illegal acts of Centocor; (iii) any breach by
Centocor of any of its representations and covenants contained in Sections 9.1
and 9.2 hereof; or (iv) any claim of patent or trademark infringement relating
34
to the Product (and in the case of trademark infringement, where Centocor is the
holder of the trademark).
10.2 SCHERING-PLOUGH INDEMNIFICATION. Schering-Plough will defend and
-------------------------------
indemnify Centocor, its Affiliates and their respective directors, officers,
employees and agents against any Losses arising out of or resulting from: (i) a
claim made against Centocor relating to the Product, but only to the extent such
Losses are caused by the negligence, willful misconduct or illegal acts of
Schering-Plough or any of its directors, officers, employees or agents in
connection, in any manner, with the sale, distribution or promotion of the
Product by Schering-Plough or other transactions contemplated by this Agreement;
(ii) any breach by Schering-Plough of any of its representations and covenants
contained in Sections 9.3 and 9.4 hereof; or (iii) any claim of trademark
infringement relating to the Product where Schering-Plough is the holder of the
trademark.
10.3 CONDITIONS TO INDEMNIFICATION. The obligations of the
-----------------------------
indemnifying party under Sections 10.1 and 10.2 are conditioned upon the
delivery of written notice to the indemnifying party of any potential Losses
within sixty (60) days after the indemnified party becomes aware of such
potential Losses. The indemnifying party shall have the right to assume the
defense of any suit or claim related to the Losses if it has assumed
responsibility for the suit or claim in writing; however, if in the reasonable
judgment of the indemnified party, such suit or claim involves an issue or
matter which could have a materially adverse effect on the business operations
or assets of the indemnified party, the indemnified party may waive its rights
to indemnity under this Agreement and control the defense or settlement thereof,
but in no event shall any such waiver be construed as a waiver of any other
indemnification rights such party may have at law or in equity. If the
indemnifying party defends the suit or claim, the indemnified party may
participate in (but not control) the defense thereof at its sole cost and
expense.
Neither party may settle a claim or action related to any Losses
without the consent of the other party, if such settlement would impose any
monetary obligation on the other party or require the other party to submit to
an injunction or otherwise limit the other party's rights under this Agreement.
Any payment made by a party to settle any such claim or action shall be at its
own cost and expense.
With respect to any claim by one party against the other arising out
of the performance or failure of performance of the other party under this
Agreement, the parties expressly agree that the liability of such party to the
other party for such breach shall be limited under this Agreement or otherwise
35
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
at law or equity to direct damages only and in no event shall a party be liable
for punitive, exemplary or consequential damages.
10.4 INSURANCE. During the period of time beginning with the first
---------
Commercial Sale and continuing for five (5) years after the expiration or
termination of this Agreement, Centocor and Schering-Plough will maintain in
force product liability insurance coverage, with commercially reasonable limits
adequate to cover their obligations under this Agreement. The insurance
obtained by Centocor shall include coverage for products with limits not less
than [*] for each claim and in the aggregate. A certificate of insurance shall
be provided by Centocor to Schering-Plough promptly after the Effective Date and
at each anniversary or renewal date of such insurance. Schering-Plough, as with
most major pharmaceutical companies, is largely self-insured for its liability
exposures. Schering-Plough's assets are sufficient to cover any contemplated
self-insured liability assumed by Schering-Plough under this Agreement.
10.5 SURVIVAL. The provisions of this Article X (other than Section
--------
10.3) will survive the termination or expiration of this Agreement.
ARTICLE XI
CONFIDENTIALITY
---------------
11.1 CENTOCOR INFORMATION. Schering-Plough will maintain in
--------------------
confidence, and will ensure that its Affiliates and its and their consultants,
employees, agents and representatives maintain in confidence, all proprietary
and confidential information which has been or is provided by Centocor to
Schering-Plough, including but not limited to, Centocor's inventions,
discoveries, improvements and methods, business plans, marketing techniques or
plans, manufacturing and other plant designs, location of operations, and any
other information affecting the business operations of Centocor ("Centocor
Information"), and will not use for any purpose other than the performance of
this Agreement, and will not publish, disseminate, or disclose, in any manner,
to any person any Centocor Information unless: (i) Schering-Plough is legally
required to do so or is required under rules or regulations of any governmental
agency or authority or any stock exchange to be disclosed, provided that
Schering-Plough shall, prior to making any such disclosure, give Centocor
sufficient advance written notice to permit it to seek a protective order or
other similar order with respect to such information and thereafter shall
disclose only the minimum information required to be disclosed in order to
comply with such law, rule or regulation, whether or not a protective order or
other similar order is obtained; (ii) the Centocor Information has entered or
enters the
CONFIDENTIAL TREATMENT REQUESTED.
36
public domain through no fault of Schering-Plough; (iii) the Centocor
Information was already known by Schering-Plough before receipt from Centocor,
or is developed independently by Schering-Plough without breach of this
Agreement, in either case as shown by contemporaneous written records; or (iv)
the Centocor Information is received by Schering-Plough from a third party under
no confidentiality obligation to Centocor.
11.2 SCHERING-PLOUGH INFORMATION. Centocor will maintain in
---------------------------
confidence, and will ensure that its Affiliates and its and their consultants,
employees, agents and representatives maintain in confidence, all proprietary
and confidential information which has been or is provided by Schering-Plough to
Centocor, including but not limited to, Schering-Plough's inventions,
discoveries, improvements and methods, business plans, marketing techniques or
plans, manufacturing and other plant designs, location of operations, and any
other information affecting the business operations of Schering-Plough
("Schering-Plough Information"), and will not use for any purpose other than the
performance of this Agreement, and will not publish, disseminate, or disclose in
any manner, to any person, any Schering-Plough Information unless: (i) Centocor
is legally required to do so or is required under rules or regulations of any
governmental agency or authority or any stock exchange to be disclosed, provided
that Centocor shall, prior to making any such disclosure, give Schering-Plough
sufficient advance written notice to permit it to seek a protective order or
other similar order with respect to such information and thereafter shall
disclose only the minimum information required to be disclosed in order to
comply with such law, rule or regulation, whether or not a protective order or
other similar order is obtained; (ii) the Schering-Plough Information has
entered or enters the public domain though no fault of Centocor; (iii) the
Schering-Plough Information was already known by Centocor before receipt from
Schering-Plough, or is developed independently by Centocor without breach of
this Agreement, in either case as shown by contemporaneous written records; or
(iv) the Schering-Plough Information is received by Centocor from a third party
under no confidentiality obligation to Schering-Plough.
11.3 SURVIVAL; SPECIFIC PERFORMANCE. The provisions of this Article
------------------------------
XI will survive the termination or expiration of this Agreement for a period of
ten (10) years. Each party agrees that money damages through arbitration would
not be a sufficient remedy for any breach by it of the provisions of this
Article XI and that, in addition to any remedy which may be available through
arbitration, the non-breaching party will be entitled to apply for and obtain
orders for specific performance and injunctive or other equitable relief as a
remedy for any such breach from a Court of general jurisdiction in the state,
federal judicial district, county or canton (as the case may be) in which the
principal place of business of the party in breach is located.
37
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
ARTICLE XII
GENERAL PROVISIONS
------------------
12.1 HUMAN ANTI-TNF ANTIBODIES. In the event Centocor develops a
-------------------------
fully human anti-TNF monoclonal antibody through use of transgenic animals or
plants or other technology, Centocor shall notify Schering-Plough of such
development efforts through the Product Committee. Schering-Plough will have
the exclusive right, until such time as Centocor successfully completes a Phase
IIb clinical trial establishing proof of efficacy for the new antibody but no
earlier than the time at which Centocor makes a milestone or equity payment to a
third party licensor due upon initiation of the clinical development of such new
antibody, to participate with Centocor in the ongoing clinical development and
commercialization of such new antibody. If Schering-Plough elects to
participate, it shall reimburse Centocor for [*] of the fully allocated costs
(i.e., personnel costs plus out-of-pocket expenses, except that Schering-Plough
shall only reimburse Centocor for [*] of any milestones Centocor has paid)
incurred to date in the development of such new antibody. If Schering-Plough
elects to participate, the new antibody shall be treated as an Improvement to
the Product under the terms of this Agreement with respect to the Territory. In
the event Schering-Plough elects not to participate, Centocor will be free to
market and sell such new antibody product in the United States and the Territory
for any and all indications or agree to sell it to one or more other parties for
resale in the United States and the Territory for one or more indications. [*]
12.2 FORCE MAJEURE. Neither party will be liable to the other for
-------------
failure or delay in the performance of its obligations hereunder, if and to the
extent that such failure or delay is attributable to any circumstance beyond its
control which it could not have avoided by the exercise of reasonable diligence
(hereinafter referred to as "Force Majeure"). The party affected by Force
Majeure will provide the other party with full particulars thereof as soon as it
becomes aware of the same (including its best estimate of the likely extent and
duration of the interference with its activities), and will use diligent efforts
to overcome the difficulties created thereby and to resume performance of its
obligations as soon as practicable. If Force Majeure prevails, or is expected
to prevail, for a period of three (3) months or more, the parties will meet to
discuss means for overcoming any difficulties, including an amendment to this
Agreement to meet the new situation.
12.3 NO AGENCY OR PARTNERSHIP. The parties intend and agree that
------------------------
nothing in this Agreement itself renders either party an agent of the other for
any purpose whatsoever and that nothing in this Agreement will be
CONFIDENTIAL TREATMENT REQUESTED.
38
construed as establishing a joint venture or partnership between the parties.
Except as otherwise provided herein, without the specific prior written approval
of the other party, neither party has authority to, and will not, enter into any
contract, make any representation, give any warranty, incur any liability or
otherwise act on behalf of the other.
12.4 NO IMPLIED LICENSES. Nothing in this Agreement is intended to or
-------------------
will be construed to create, confer, give effect to or otherwise imply in
Schering-Plough any license, right or property interest in the Product, any
Centocor patent, patent application or patent rights, any Centocor trademark or
trade name, or any other Centocor property, except as expressly set forth
herein. Schering-Plough will not, through any action or inaction, cause any
prejudice to or dilution of Centocor's trademark or patent rights (including
patent applications). Nothing in this Agreement is intended to or will be
construed to create, confer, give effect to or otherwise imply in Centocor any
license, right or property interest in any Schering-Plough trademark or trade
name except as provided in Section 4.3(b). Centocor will not, through any
action or inaction, cause any prejudice to or dilution of Schering-Plough's
trademarks.
12.5 THIRD PARTY INFRINGEMENT.
------------------------
(a) NOTICE. If either party becomes aware of any infringement or
------
threatened infringement of any patent, trademark or other property right
relating to the Product, then the party having such knowledge will give written
notice to the other within twenty (20) days of becoming aware of such
infringement or threatened infringement. Any such notice shall include evidence
to support an allegation of infringement by such third party.
(b) CENTOCOR'S PROSECUTION RIGHTS. Centocor, in consultation with
-----------------------------
Schering-Plough, will have the right, but not the obligation, to institute,
prosecute, and control any action or proceeding with respect to the infringement
of patents, trademarks (where Centocor is the holder of the Trademark or a
trademark for the Product) or other property right relating to the Product.
Centocor shall bear all the expenses of any suit brought by it. Schering-Plough
shall have the right, prior to commencement of the trial, suit or action brought
by Centocor, to join any such suit or action, and in such event shall pay one-
half of the costs of such suit or action. In the event that Schering-Plough has
joined in the action and shared in the costs thereof as set forth above, no
settlement, consent judgment or other voluntary final disposition of the suit
may be entered into without the consent of Schering-Plough. In the event that
Schering-Plough has not joined the suit or action, Schering-Plough will
reasonably cooperate with Centocor in any such suit or action and shall have the
right to consult with Centocor and be represented by
39
THE REGISTRANT HAS REQUESTED CONFIDENTIAL TREATMENT FOR CERTAIN
PORTIONS OF THIS AGREEMENT. THOSE PORTIONS HAVE BEEN OMITTED FROM THIS COPY OF
THE AGREEMENT AT THE PLACES INDICATED BY ASTERISKS (*); AND HAVE BEEN FILED
SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.
its own counsel at its own expense, provided that Centocor shall periodically
reimburse Schering-Plough for its out-of-pocket costs (excluding the costs of
retaining its own outside counsel) incurred in cooperating with Centocor. Any
recovery or damages derived from a suit which Schering-Plough has joined and
shared costs shall be used first to reimburse each of Centocor and Schering-
Plough for its documented expenses with respect thereto, with any remaining
amounts to be shared equally by the parties. Any recovery or damages derived
from a suit which Schering-Plough has not joined shall be retained by Centocor.
(c) SCHERING-PLOUGH'S PROSECUTION RIGHTS. Where Schering-Plough is
------------------------------------
the holder of the Trademark or a trademark for the Product, Schering-Plough, in
consultation with Centocor, will have the right, but not the obligation, to
institute, prosecute, and control any action or proceeding with respect to the
infringement of the Trademark or of such trademark for the Product. Schering-
Plough shall bear all the expenses of any suit brought by it. Centocor shall
have the right, prior to commencement of the trial, suit or action brought by
Schering-Plough, to join any such suit or action, and in such event shall pay
one-half of the costs of such suit or action. In the event that Centocor has
joined in the action and shared in the costs thereof as set forth above, no
settlement, consent judgment or other voluntary final disposition of the suit
may be entered into without the consent of Centocor. In the event that Centocor
has not joined the suit or action, Centocor will reasonably cooperate with
Schering-Plough in any such suit or action and shall have the right to consult
with Schering-Plough and be represented by its own counsel at its own expense,
provided that Schering-Plough shall periodically reimburse Centocor for its out-
of-pocket costs (excluding the costs of retaining its own outside counsel)
incurred in cooperating with Schering-Plough. Any recovery or damages derived
from a suit which Centocor has joined and shared costs shall be used first to
reimburse each of Centocor and Schering-Plough for its documented expenses with
respect thereto, with any remaining amounts to be shared equally by the parties.
Any recovery or damages derived from a suit which Centocor has not joined shall
be retained by Schering-Plough.
(d) ASSIGNMENT OF PROSECUTION RIGHTS. In the event one party (the
--------------------------------
"Owning Party") does not exercise its prosecution right according to Sections
12.5(b) or (c), as the case may be, to prevent or eliminate the infringement
within [*] days of receipt of notice of the infringement or threatened
infringement thereof, the other party (the "Other Party") may, at its option,
give notice to the Owning Party that unless the Owning Party undertakes such
action the Other Party will commence an action to terminate such infringement.
If the Owning Party fails to take such action within [*] days of such notice
then the Other Party will have the right, but not
CONFIDENTIAL TREATMENT REQUESTED.
40
the obligation, to take such action as it deems appropriate against any
infringer at its own cost. The Owning Party shall provide reasonable assistance
to the Other Party in any suit for infringement brought by such Other Party
against a third party, and shall have the right to consult with the such Other
Party and to participate in and be represented by outside counsel in such
litigation at its own expense. For purposes of this Section 12.5(d), reasonable
assistance shall mean the Owning Party providing the Other Party reasonable
access to information, materials and personnel which such Other Party reasonably
determines is necessary to enable the Other Party's conduct of the suit. The
Other Party shall periodically reimburse the Owning Party for its out-of-pocket
costs (excluding Owning Party's costs of retaining outside counsel) incurred in
cooperating with the Other Party. The Other Party shall incur no liability to
the Owning Party as a consequence of such litigation or any unfavorable decision
resulting therefrom, including any decision holding any of the patent rights or
trademarks invalid or unenforceable. In the event that the Other Party recovers
any sums in such litigation by way of damages or in settlement thereof, the
Other Party shall have the right to retain all such sums to offset its costs,
losses and expenses.
12.6 THIRD PARTY CLAIMS. If either party becomes aware of any action
------------------
or suit, or threat of action or suit, by a third party alleging that the
manufacture, use or sale of the Product in the Territory infringes a patent,
trademark or any other proprietary right of any third party, the party aware
will promptly notify the other party of the same and fully disclose the basis
therefor. Subject to Sections 10.1 and 10.2, (i) either party agrees to
cooperate and consult with the other party during the course of the defense of
such action or suit or threat of action or suit and to keep the other party
informed in respect of all significant aspects of such defense, and (ii) neither
party will settle any such action or suit or threat of action or suit without
the express written consent of the other party, which consent will not be
unreasonably withheld.
12.7 ARBITRATION AND LIMITATION OF DAMAGES. Any unresolved dispute
-------------------------------------
between the parties or any claim of one party against the other arising under or
in connection with this Agreement will be resolved through binding arbitration
pursuant to the mechanism set forth in Appendix K; provided, however, that no
party will refer a dispute to arbitration under this Section without giving at
least twenty (20) days' notice to the Oversight Committee of its intention to do
so.
12.8 MODIFICATION; ASSIGNMENT. This Agreement may be modified or
------------------------
amended only in writing signed by duly authorized representatives of Centocor
and Schering-Plough. Neither party shall assign this Agreement or any of its
rights or obligations under this Agreement without the prior
41
written consent of the other party hereto and any attempted assignments without
that written consent will be void; provided, however, that such consent will not
be unreasonably withheld. Notwithstanding the previous sentence, this Agreement
may be assigned by either party to an Affiliate of that party.
12.9 NOTICES. All notices required or provided under this Agreement
-------
will be given in writing and will be deemed to have been properly served if
delivered by hand (including delivery by courier), or sent by registered or
certified mail or sent by telefax confirmed by registered or certified mail in
each case to the following addresses:
To Centocor: To Schering-Plough:
Centocor, Inc. Schering-Plough Ltd.
000 Xxxxx Xxxxxx Xxxxxxx Xxxxxxxxxxxxxx 0
Xxxxxxx, Xxxxxxxxxxxx 00000 XX-0000 Xxxxxxx
Xxxxxxxxx: Secretary Switzerland
Fax: 000-000-0000 Attention: President
Fax: 00-00-0000000
with copies to:
Schering Corporation
0000 Xxxxxxxxx Xxxx Xxxx
Xxxxxxxxxx, Xxx Xxxxxx 00000
Attention: Vice President,
Business Development
Fax: (000) 000-0000
and
Schering Corporation
0000 Xxxxxxxxx Xxxx Xxxx
Xxxxxxxxxx, Xxx Xxxxxx 00000
Attention: Senior Legal
Director, Licensing
Fax: (000) 000-0000
or such other address as may be specified in a written notice by the party to
whom notice is to be given. Notices will be deemed to have been delivered as
follows: if sent by mail, seven (7) days after the date of posting; if
delivered by hand, on the date of delivery; if sent by telefax, on the date of
transmission at the place of business of the recipient.
42
12.10 ENTIRE AGREEMENT. This Agreement supersedes all prior
----------------
agreements and understandings between Centocor and Schering-Plough with respect
to the subject matter hereof. This Agreement contains the entire understanding
and agreement between Centocor and Schering-Plough with respect to the subject
matter hereof and the terms of this Agreement will govern over conflicting terms
of any purchase order or invoice delivered under this Agreement. The Article
and Section headings contained in this Agreement are for convenience of
reference only and will not be considered when interpreting this Agreement.
12.11 PUBLIC STATEMENTS. Neither party, nor its representatives and
-----------------
employees, will make any oral or written disclosure, including any news release
or other public statement, whether to the press, stockholders, or otherwise,
disclosing the existence or terms of this Agreement or of any amendment hereto,
without the prior written approval of the other party, which approval will not
be unreasonably withheld or delayed; provided that nothing in this Section will
be deemed to prevent either party from making such disclosures or statements
which, in the opinion of counsel, are legally required. In the event such
disclosure or statement is required, the disclosing party will give prior notice
to the other party of the proposed disclosure or statement and the reason
therefor. The parties anticipate that on or after the Effective Date they will
issue a press release in a form to be mutually agreed upon by the parties, and
thereafter may from time to time issue additional press releases as mutually
agreed upon by the parties. Following any such press release, either party
shall have the right to issue subsequent public disclosures containing the same
information as that contained in the previously agreed upon press releases.
12.12 GOVERNING LAW; DISPUTES. This Agreement will be governed by
-----------------------
and construed in accordance with the internal laws of the Commonwealth of
Pennsylvania without regard to conflicts of laws provisions. The parties
expressly exclude application of the United Nations Convention for the
International Sale of Goods.
12.13 NO WAIVER. Except as specifically set forth in this Agreement,
---------
no failure or delay on the part of a party in exercising any right hereunder
will operate as a waiver of, or impair, any such right. No single or partial
exercise of any such right will preclude any other or further exercise thereof
or the exercise of any other right. No waiver of any such right will be deemed
a waiver of any other right hereunder.
12.14 COUNTERPARTS. This Agreement may be executed in counterparts,
------------
each of which will be an original and all of which will constitute together but
one and the same document.
43
12.15 FILINGS AND NOTIFICATION. As soon as practicable after the
------------------------
execution of this Agreement, and if deemed necessary, the parties will ensure
that this Agreement is jointly notified to the Commission of the European
Communities in accordance with Regulation 17 of 1962 of the Council of the
European Communities seeking negative clearance or exemption under Article 85(3)
of the EC Treaty or both.
12.16 RELATED AGREEMENTS. Concurrently herewith the parties have
------------------
entered into a License Agreement and a Security Agreement, which are attached
hereto as Appendices L and M, respectively, granting to Schering-Plough rights
under certain patents and patent applications relating to the Product, and a
security interest in the Trademark or trademarks and the good will connected
with and symbolized by the Trademark or trademarks, in each country in the
Territory. Centocor agrees to execute, acknowledge and deliver such further
instruments and to do all such other acts, at Schering-Plough's expense, as may
be reasonably required to perfect Schering-Plough's rights under those
agreements.
IN WITNESS WHEREOF, Centocor and Schering-Plough have caused this
Agreement to be executed by their duly authorized representatives as of the date
first written above.
CENTOCOR, INC. SCHERING-PLOUGH LTD.
By: /s/ Xxxxxx X. Xxxxxxx By: /s/ Xxxxxx X. Xxxxx
-------------------------- -----------------------
Title: President and Chief Title: Manager (Direktor)
Operating Officer
Date: April 3, 1998 April 3, 1998
44
